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ABSTRACT
Introduction: The role of hyperhomocysteinemia in psychotic disorder can be explained by partial an-
tagonism of homocysteine on NMDA-glycine receptor. Plasma concentration of homocysteine is an indi-
cator of the status of the B-vitamins (folate, B12, B6). Folate defi ciency may have different effects on the 
neurochemical processes of schizophrenia. This suggests that the association between elevated levels of 
homocysteine and schizophrenia is biologically very likely. 
Methods: The study was consisted of 20 patients with schizophrenia and 20 healthy controls. We inves-
tigated the levels of serum homocysteine concentration using AxSYM (Abbott), levels of folate assay is 
two-step immunoassay to determine the presence folate in human serum using CMIA (chemiluminescent 
microparticle immunoassay) technology and Axsym Holo Tc is microparticle enzyme immunoassay (MEIA) 
for the quantitative determination of human holo TC in serum and determination defi cit of vitamin B 12.
Results: The patients group has higher levels of homocysteine in compare with controls group for 3.85 
μmol/L while the concentration of folate in the group of patients was lower for 9.17 ng/mL. The mean 
level of vitamin B-12 in investigation groups were in reference range 19.1-119 pmol/L, but patient group 
have lower average concentration of vitamin B-12 lower for 24.81 pmol/L compared to the control group. 
Conclusion: Our results showed that homocysteine concentration is inversely proportionate to folate con-
centration, i.e. as homocysteine concentration in serum increases, folate concentration falls. Shizophrenic 
patients with elevated tHcy level and low folate levels should have vitamin supplementation with folic acid.
Keywords: Schizophrenia, homocysteine, folate, vitamin B-12.
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INTRODUCTION
Conceptualization of glutaminergic system in the 
last fi fty years follows the historical development 
of models phencyclidine (PCP) in patients who 
suff ering from schizophrenia, a description of its 
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psyhomimetic eff ect, through the discovery of N-
methyl-D-aspartate glutamat receptor (NMDAR), 
and fi nally the nineties years set new treatment 
strategies to base on these receptors (1, 2). NMDAR 
antagonists induce an increase of the positive and 
negative symptoms of schizophrenia. In this connec-
tion we now have several hypotheses that explain the 
mechanism by which NMDAR dysfunction leads to 
abnormalities in thinking, perception disorders, bi-
zarre behavior and cognitive damage, which schizo-
phrenia remains of intrigue when it comes to the 
status of reality as the notion of mental deteriora-
tion, as well as several theories in the new concept of 
treatment. Oxidation of homocysteine leads to the 
formation homocysteine sulfuric acid and homocys-
teine acid; both products have expressed excitotoxic 
action of the diff erent subtypes of the N-methyl-D-
aspartate (NMDA) glutamat receptor. Excitotoxic 
cell type was observed when human cells in diff erent 
parts of the brain exposed to homocystein excito-
toxic acids and amino acids. Recent studies in rats 
have shown that homocysteine causes DNA damage 
to neurons inducing apoptosis of hypersensitivity 
to excitotoxicity. In, the brain, there is a limited ca-
pacity for homocysteine methabolism. In addition, 
folate metabolism play a critical roles in the meth-
abolism of homocysteine (4). Th e level of 5-me-
thyltetrahydrofolate in cerebrospinal fl uid is at least 
three times that found in plasma and an active trans-
port process exists at the blood-brain-barrier. Th e fo-
lates have important role in the brain and the neces-
sity for protection agains the eff ects of defi ciency (5). 
Tests on rats have shown that elevated homocysteine 
leads to apoptosis of neurons in the hippocampus. 
Relatively large storage of folate in CSF provides the 
brain with folate and thereby protects nerve cells 
from the toxic eff ects of increased concentrations of 
homocysteine. Besides folate defi ciency may have 
diff erent eff ects on the neurochemical processes of 
schizophrenia, because it works as a carbon donor 
in the synthesis of glycine from serine. Folate is also 
involved in the synthesis of dopamine, norepineph-
rine and serotonin through pathways the methyla-
tion of S-adenosyl-methionine and conversion of 
methionine to homocysteine (6). Homocysteine is 
an amino acid produced by demethylation of me-
thionine, an essential amino acid that in the body 
intake of food. Homocysteine was fi rst described 
in 1932 in the works by Butz and Vigneauda that 
homocysteine synthesis activity concentrated strong 
acid on methionine. In the body comes from food 
or produced during degradation of endogenous pro-
teins. Methyl group of methionine is activated by 
switching to S-adenosyl-methionine (SAM). Th e 
reaction catalyzes of L-methionine-S-adenoziltrans-
feraza the presence of ATP. After the transfer of the 
methyl group exceeds S-adenosyl-methionine in 
tioester S-adenosyl-homocysteine (SAH). S-adeno-
syl-methionine is a donor of numerous reactions in 
the brain, including many that are involved in the 
synthesis and metabolism of monoamines such as 
dopamine, norepinephrine and serotonin (6). Th is 
suggests that the association between elevated levels 
of homocysteine and schizophrenia is biologically 
very likely. Numerous epidemiological studies have 
linked increased levels of homocysteine with vascu-
lar disease, dementia, defects of fetal development, 
increasing the level of mortality and with neuropsy-
chiatric disorders (2) such as schizophrenia, bipolar 
aff ective disorder and depression (6,7,8). Homocys-
teine is at about 45% of elderly patients increased 
and its concentration correlates well with the sever-
ity of the memory functions. Th erefore homocyste-
ine it is better for diagnosis of cognition (cognitive 
impairment) than the concentration of folate and 
vitamin B12 in serum (9). 
Today there is interest in measuring the biologically 
active form of cobalamin. Th e vitamin B 12 (cobala-
min) in serum is bound to two proteins, transco-
balamin (TC) and haptocorrin (HC). About 20% 
of cobalamin is related to transcobalamin and it is 
biologically active, while 80% is related to hapto-
corrin is biologically inactive. Th e transcobalamin-
vitamin B-12 complex is called holotranscobalamin 
(Holo Tc) and it is used in vitro diagnostic assay for 
the quantitative determination of cobalamin. Th e 
reduced concentration of Holo Tc, it is an indicator 
of defi cit vitamin B 12. Notably, low values have 
been reported in vegetarians and populations with 
low intake of vitamin B 12. Th e tests for measuring 
total vitamin B 12 are based on the measurement 
of active and inactive fractions, but very often do 
not correlate with existing symptoms of the defi cit. 
Th e reference area of vitamin B 12 is diffi  cult to de-
termine because it is too close to «normal» samples. 
Holo Tc levels refl ect vitamin B 12 status, indepen-
dent of recent absorption of the vitamin (10,11). 
Homocysteinaemia is a newly defi ned term con-
nected to the increased risk of atherothrombotic 
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and atherosclerotic systemic and retinal vascular oc-
clusive diseases, and its role in the course of many 
anatomical or functional abnormalities of the ves-
sels of the optic nerve head such as arteriosclerosis 
or vascular dysregulation, homocistein might be the 
causative factor (12,13). Some studies showed that 
elevated Hcy may increase the risk of retinal vascu-
lar diseases, such as retinal artery and vein occlusion 
and non-artheritic ischemic optic neuropathy (14, 
15). Hcy-induced vascular problem may be a mul-
tifactorial case, including direct toxic damage to the 
endothelium, stimulation of proliferation of smooth 
muscle cells, enhanced low density lipoprotein per-
oxidation, increased platelet aggregation, and eff ects 
upon the coagulation system (16). 
Maybe, this reason of much work in the cognitive 
neuroscience of schizophrenia has focused on at-
tention, memory, and executive functioning. To 
date, less work has focused on perceptual process-
ing. However, perceptual functions are frequently 
disrupted in schizophrenia, and thus this domain 
has been included available ophthalmology tests in 
this article, how we can describe the basic science 
presentation and the breakout group discussion on 
the topic of perception when we use some test for 
the assessment of cognitive function in schizophre-
nia. Th e importance of perceptual dysfunction in 
schizophrenia, the nature of perceptual abnormali-
ties in this disorder, and the critical need to develop 
perceptual ophthalmology tests appropriate for fu-
ture clinical trials and validity of some tests for the 




Th e patients group consisted of inpatients (n=20) 
with Schizophrenia (Sch) diagnosed according to the 
tenth revision of the International Classifi cation of 
Diseases (ICD-10), treated at the Psychiatric Clin-
ic, Clinical Centre University of Sarajevo (CCUS). 
Th e patients were followed for eight weeks during 
2012. All participants signed an informed consent 
and study was approved by the Ethics Committee 
of the Clinical Center of the University of Sarajevo. 
Th e study was, for the most part, conducted via the 
prospective method of clinical research and partly as 
a descriptively controlled study. Th e patients were 
treated with typical antipsychotics (haloperidol and 
fl uphenazine) (n = 14) and atypical antipsychotics 
(olanzapine and risperidone) (n = 6) for at least eight 
weeks. 
Th e inclusion criteria were female and male patients 
with a diagnosis of schizophrenia according to ICD-
10 criteria (International Classifi cation of Diseases); 
Th e presence of positive and negative symptoms, 
cognitive defi cits and functioning on a social level; 
Antipsychotic therapy, typical or atypical; Subjects 
18-65 years of age; One or more hospitalizations. 
Th e exclusion criteria were comorbidity; organic 
brain damage; other medical conditions (diabetes 
mellitus, hypertension, neurological disorders, in-
fl ammatory disease or gastroenterological disease); 
alcohol and drug abuse.
Blood samples
Th e patient samples of blood were collected in se-
rum separation Vacutainer test tubes (Beckton 
Dickinson, Rutherford, NJ 07,070 U.S.) in volume 
of 3.5 mL. Test tubes with gel were used. After col-
lection, samples were placed in ice and after 30 to 60 
minutes, samples were obtained by centrifugation 
at 3000 rpm using centrifuge (Sigma 4-10). After 
centrifuging, serum concentration of homocysteine, 
folate, active form of vitamin B-12 and creatinine 
were determined.
Determination of homocysteine (Hcy) 
Th e value of serum homocysteine concentration 
was determined using AxSYM (Abbott), based on 
measurements of fl uorescence polarization immu-
noassay (FPIA) technology. Th e reaction principle 
is conversion of homocystine, mixed disulfi de and 
protein-bound forms of homocysteine in the sample 
to form of free homocysteine by the use of dithio-
threitol (DTT). After that free homocysteine is con-
verted to S-adenosyl-L-homocysteine (SAH). Under 
physiological conditions, SAH - hydrolases converts 
SAH to homocysteine. Existing methods is to de-
termine L-homocysteine in human serum. Normal 
concentration of homocysteine in serum of women 
is 3.36-20.44 μmol/L and in men is 5.90-16 μmol/L 
(17). Th e creatinin was determined using automatic 
analyzer Dimension (Dade Behring). Method for 
determination of creatinine is a modifi cation of the 
kinetic reaction of Jaff ee. Th e reference value for 
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serum creatinine concentration is 45-115 μmol/ L 
(18). 
Determination of folate
All immunoassays require the use of labeled material 
in order to measure the amount of antigen or anti-
body. A label is a molecule that will react as a part of 
the assay, so a change in signal can be measured in 
the blood after added reagent solution. CMIA (che-
miluminescent microparticle immunoassay) is non-
competitive sandwich assay technology to measure 
analytes. Th e amount of signal is directly propor-
tional to the amount of analyte present in the sam-
ple. Architect folate asssay is two-step immunoassay 
to determine the presence folate in human serum 
using CMIA technology. Two pre-treatment steps 
mediate the release of folate from endogenous fo-
late binding protein. In pre-treatment step 1 sample 
ans pre-treatment reagent 2 (dithiothreitol or DDT) 
are aspirated and dispensed into a reaction vessels 
(RV). In pre-treatment step 2, an aliquot of sample/
pre-treatment reagent 2 mixture is aspirated and 
dispensed into a second RV. Pre-treatment reagent 
(KOH) is then added. An alliquot of the pre-treated 
sample is transfered into a third RV, followed by 
the addition of folate binding protein (FBP) coated 
paramagnetic microparicles and assay specifi c dilu-
ent. Folate presented in the sample binds to the FBP 
coated microparticles. After washing, pteroic acid-
acridinium labeled conjugate is added and binds to 
unoccupied sites on the FBP-coated microparticles. 
Following another incubation and wash, pre-trigger 
and trigger solutions are then added to the reaction 
mixture. Th e pre-trigger solution (hydrogen perox-
ide) creates an acidic environment to prevent early 
release of energy (light emission), helps to keep mic-
roparticles from clumping and splits acridinium dye 
off  the conjugate bound to the microparticle com-
plex (this action prepares the acridinium dye for the 
next step). Th e trigger solution (sodium hydroxide) 
dispenses to the reaction mixture. Th e acridinium 
undergoes an oxidative reaction when is exposed 
to peroxide and an alkaline solution. Th is reaction 
causes the occurence of chemiluminescent reaction. 
N-methylacridone forms and releases energy (light 
emission) as it returns to its ground state. Th e re-
sulting chemiluminescent reaction is measured as 
relative light units (RLU). A direct relationship ex-
ists between the amount of folate in the sample and 
RLU detected by Architect System optics. Th e refer-
ence value for serum folate concentration is 7.0-31.4 
ng/mL (19).
Determination of active B-12 
Axsym Holo Tc is microparticle enzyme immuno-
assay (MEIA) for the quantitative determination of 
human holo TC in serum and determination defi cit 
of vitamin B 12. Microparticles are coated with an 
Anti-Holo Tc monoclonal antibodies in the pres-
ence of human antigens on the Holo Tc micropar-
ticles arises immune complex. On Anti-Holo Tc an-
tibodies present a conjugate of alkaline phosphatase 
in the next reaction, which reacts with the substrate 
4-methylumbelliferyl phosphate (MUP). Th e result-
ing fl uorescent product is measured by MEIA opti-
cal system. Th e reference value for the healthy popu-
lation Holo Tc is 19.1-119 pmol/L (20).
Statistical analysis
Th e results were statistically analysed using SPSS 
version 12 and Microsoft Offi  ce Excel 2003. Aver-
age values, standard deviation (SD) and Pearson cor-
relation coeffi  cient (r) were calculated, as well Wil-
coxon signed rang test with statistical signifi cance 
level of 0.05 P<0.05. 
RESULTS
Th e investigation included 20 patients with shizo-
phrenia and 20 healty subjects. Th e study included 6 
(30%) men and 14 (70%) women in control group. 
Th e group with shizophrenia have 5 (25 %) men 
and 15 (75%) women. Th e average age in the con-
trol group was 49.45 years and in shizophrenia pa-
tients was 44.5 years. Normal homocysteine concen-
tration in serum is 3.36-20.44 μmol/L for women 
and 5.90-16 μmol/L for men. Th e reference folate 
concentration is 7.0-31.4 ng/mL and vitamin B-12 
19.1-119 pmol/L. 
Th e mean concentration of homocysteine, folate 
and vitamin B-12 in shizophrenia patients and con-
trol group are shown in Table 1. Th e patients with 
shizophrenia have higher levels of homocysteine in 
compare with controls group for 3.85 μmol/L while 
the concentration of folate in the group of patients 
was lower for 9.17 ng/mL. Th e patients with shizo-
phrenia have a folate defi ciency. Th e mean level of 
vitamin B-12 in investigation groups were in ref-
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erence range 19.1-119 pmol/L, but patient group 
have lower average concentration of vitamin B-12 
lower for 24.81 pmol/L compared to the control 
group. Folate defi ciency signifi cantly changes the 
concentration of homocysteine, which could aff ect 
the diff erences between patients with shizophrenia 
and control group.
It is indicated that high level of homocysteine fol-
lows low level of folate in serum at patients with 
shizophrenia. 
We have shown in Table 2. Z and P values mean 
serum homocysteine, folate and vitamin B-12 con-
centration in patients and control subjects. Using 
Wilcoxon signed ranks test we have concluded that 
average concentration of homocysteine in shizophre-
nia patients were signifi cantly diff erend (P<0.05) 
from serum concentration in control subjects. Th ere 
was a signifi cant diff erence in folate serum concen-
tration between patient group and control group 
for P<0.05. According Wilcoxon signed ranks test 
mean vitamin B-12 concentration was signifi cant 
for P<0.05 in investigated groups. 
Th e correlation between homocystein and vitamin 
levels in patients serum are shown in Table 3. Th ere 
was a signifi cant diff erence between the mean serum 
homocysteine and folate (P <0.05) with a negative 
Pearson correlation coeffi  cient (r = -0.52) in the 
group of patients. Using the same test, a signifi cant 
diff erence between the mean serum homocysteine 
and vitamin B-12 (p <0.05) with a negative Pearson 
correlation coeffi  cient (r = - 0.47). 
DISCUSSION
Th e role of hyperhomocysteinemia in psychotic 
disorder can be explained by partial antagonism 
of homocysteine on NMDA-glycine receptor (21). 
Epidemiological studies show a correlation between 
total plasma homocysteine concentration and the 
risk of neurodegenerative diseases (22). Plasma con-
centration of homocysteine is an indicator of the sta-
tus of the B-vitamins (folate, B12, B6). It was found 
that the values of homocysteine levels are signifi -
cantly elevated in young male patients with schizo-
phrenia and BP, especially those who show signs of 
cognitive deterioration, compared to the general 
population (23). However, there are studies whose 
results indicate no diff erence in homocysteine levels 
between bipolar patients and healthy controls (24). 
Increased levels of homocysteine can cause apoptosis 
and exocytosis as important mechanisms of neuro-
degeneration. Th e brain tissues utilize three mecha-
nisms for maintaining low steady state concentra-
tions of homocysteine: 1) effi  cient recycling through 
cobalamin-dependent methionine synthase, given 
an adequate supply of cobalamin and folate; 2) ca-
tabolism throught CBS to cystathionine; 3) export 
homocysteine into the circulation (25). In our study 
group patients with shizophrenia have higher levels 
of homocysteine in compare with controls group for 
3.85 μmol/L while the concentration of folate in the 
group of patients was lower for 9.17 ng/mL. Our 
results are compared with the results Mabrouk et al 
(26) have shown that the increased value of homo-
cysteine and a lower value of folate in patients with 
schizophrenia compared with the control group. 
Th e low folate status in schizophrenics and folate-re-
sponsive schizophrenic-like behavior are connected 
with defi ciency of MTHFR of TT genotype (27).  









Xsr 14.22 5.94 54.00
S.D. 4.19 2.30 23.65
S.E. 0.93 0.51 5.28
Control group 
(N=20)
Xsr 10.37 15.11 78.81
S.D. 2.16 7.00 24.25
S.E. 0.48 1.56 5.42
TABLE 1.  The mean concentration of homocysteine, folate 
and vitamin B-12 in shizophrenia patients and control group.
Homocysteine Folate  Vitamin B-12
Z - 2.800 -3.920 - 2.800
P 0.005* 0.000* 0.005*
TABLE 2.  Comparison of serum concentration of homocys-
teine, folate and vitamin B-12 in shizophrenia patients and 
control group.




r - 0,52 -0,47
p 0,017* 0,035*
TABLE 3.  Correlation between homocysteine and vitamins in 
patients with shizophrenia.
* Statistical signifi cant for P<0.05
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homocysteine in patients group with schizophrenia 
than in the control group, but no signifi cant diff er-
ences in the values of folate and vitamin B12, which 
is possible due to prolonged use of typical neurolep-
tics. Th ese results are not consistent with our results 
because we also had a larger number of patients who 
were treated with typical neuroleptics. In our study 
presented Z and P values mean serum homocysteine, 
folate and vitamin B-12 concentration in patients 
and control subjects. Using Wilcoxon signed ranks 
test we have concluded that average concentration 
of homocysteine in shizophrenia patients were sig-
nifi cantly diff erend (P<0.05) from serum concentra-
tion in control subjects. Th e reason for this is the 
cours of the illness, because in the work of Erna et 
al it was a chronic schizophrenic patient. Low fo-
late/high homocysteine level leads to increased sen-
sitivity of neurons and brain damage. We get the 
following results, there was a signifi cant diff erence 
between the mean serum homocysteine and folate 
(P <0.05) with a negative Pearson correlation coef-
fi cient (r = -0.52) in the group of patients. Using the 
same test, a signifi cant diff erence between the mean 
serum homocysteine and vitamin B-12 (p <0.05) 
with a negative Pearson correlation coeffi  cient (r = 
- 0.47). We have got a good correlation of homo-
cystene with folate and vitamin B-12. Th e negative 
Pearson correlation coeffi  cient we could explain that 
high level of homocysteine is probably resulted with 
low folat serum concentration. In our study we have 
got vitamin B-12 in reference range which could be 
explained with wide range of vitamin B-12 in hu-
man body. Epidemiological studies have found a 
link between folate defi ciency and hyperhomocys-
teinemia in neurodegenerative and neuropsychiatric 
disorders, including Alzheimer's and Parkinson M., 
depression and schizophrenia. Th ere is also evidence 
on the connection between B-vitamin defi ciency 
and depression (29). Folic acid and SAM can be 
used as a complementary means for the treatment 
of depression. On the other hand, folate defi ciency 
in depressed patients may be a consequence of inad-
equate nutrition. Regardless of whether folate defi -
ciency in primary or secondary depression, admin-
istration of folate may be useful in recovering from 
depression and improve mental status. It would be 
interesting to extend our research to other psychiat-
ric diagnostic groups such as depression and bipolar 
aff ective disorder. 
It is known that a diet rich in animal protein may in-
crease, and foods rich in beans and green vegetables 
to lower homocysteine levels. Diff erent groups of 
drugs, such as drugs for lowering fat (fi brates and 
niacin), oral hypoglycemics (metformin), insulin, 
drugs used to treat rheumatoid arthritis and anti-
convulsants may cause an increase in serum levels 
of homocysteine (30), which could in the future be 
interesting in expanding the study introduce more 
detailed and complete test diet. With regard to gen-
der diff erences in the prevalence of hyperhomocyste-
inemia results of numerous studies indicate that the 
values of homocysteine levels are generally higher in 
men (31). All of the above would be fully subject of 
our next study, given that they are now working on 
the preliminary results.
CONCLUSION
Th ese fi ndings support the hypothesis that altered 
levels of homocysteine, folate and vitamin B12 may 
coexist in patients with schizophrenia and contrib-
ute to pathophysiological aspects of this illness. Th e 
homocysteine could be an independent risk fac-
tor for neuropsychiatric disorders and risk factor 
for development of cerebrovascular disease. In our 
group of shizophrenia patients we have a limited 
number of patients and we have not informations 
about concentration of homocysteine, folate and 
vitamin B-12 during shizophrenia treatment. Th e 
hyperhomocysteinemia is presented in about 25 % 
and low folat leves in 60 % of shizophrenia patients. 
In patients group homocysteine level were elevated 
compared to the levels of controls when folate levels 
were low, these resuls indicate that enzymatic defect 
could be involved. Our results showed that homo-
cysteine concentration is inversely proportionate to 
folate concentration, i.e. as homocysteine concen-
tration in serum increases, folate concentration falls. 
Th e shizophrenia patients with elevated tHcy level 
and low folate levels should have vitamin supple-
mentation with folic acid. Th is would be the view 
of the preliminary results of our research, which in 
the future demanded a larger sample, the relation-
ship between these biochemical parameters related 
to the predominance of positive or negative symp-
toms of schizophrenia, with the inclusion of other 
diagnostic entities, depression and bipolar aff ective 
disorder, and complete processing of data related to 
the metabolic syndrome and nutrition, which will 
be planned. 
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